Huls, Gerwin <br/><br/>
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.  [electronic resource] 

 -  Blood  Jul 2010 
 - 180-2 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2010-01-263087  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged, 80 and over<br/>Anabolic Agents--therapeutic use<br/>Anemia, Refractory--drug therapy<br/>Anemia, Sideroblastic--drug therapy<br/>Antineoplastic Agents--therapeutic use<br/>Erythropoietin--therapeutic use<br/>Humans<br/>Hypertension, Pulmonary--complications<br/>Janus Kinase 2--genetics<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Mutation<br/>Pulmonary Embolism--complications<br/>Pyridoxine--therapeutic use<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Thalidomide--analogs & derivatives<br/>Thrombocytosis--drug therapy<br/>Vitamin B Complex--therapeutic use